ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.83 -0.60%

-$0.13 today

Market cap
$3.08B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.89M

Average 1.66M

ACAD Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

ACADIA Pharmaceuticals Inc.NASDAQ: ACAD

Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Free cash flow declines year over year

Q2 FY2026 free cash flow of $124.46M fell 23.4% year over year, behind the -6.8% change in trailing-twelve-month free cash flow. Sequentially, it rose 332.6% from the prior quarter.

Context

  • Free cash flow amounted to 9.8% of revenue in FY2025, down 6.6 pp from a year earlier.
  • Free cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -23.4% toward the trailing-twelve-month pace of -6.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$124.46M+332.6% QoQ
Last fiscal yearDec 2025
$105.15M-33.1% YoY
LTMJun 2026
$174.39M-6.8% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.4%——
1 year-33.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
105.15M USD
Year-over-year change
-33.1%

Free Cash Flow vs competitors

How ACAD compares with its peers on the latest reported figures

  • ACAD's LTM Jun 2026 free cash flow of $174.39M is the 3rd largest of the 11 companies compared; the peer median is $76.05M.
  • Its year-over-year change of -6.8% is the 9th highest of 10, against a peer median of +16.8%.
  • Free cash flow amounts to 15.3% of revenue for ACAD, versus a peer median of 58.5%.
ACAD Competitors Peer median
Free Cash Flow for ACAD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$323.78M +41.8%+10.3%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$193.4M -3.0%+21.4%—
ACADACADIA Pharmaceuticals Inc.LTM Jun 2026$174.39M -6.8%—15.3%
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$164.26M +92.8%+71.8%—
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$127.3M +121.8%—58.5%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$80.71M +16.8%+192.3%403.5%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$71.39M -40.9%-7.1%9.2%
ANROAlto Neuroscience, Inc.LTM Mar 2026$62.86M +14.6%+34.8%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$57.66M +45.8%+40.0%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$51.71M —+134.7%—
AVXLAnavex Life Sciences Corp.LTM Dec 2025$34.08M -4.3%+17.2%—
Peer median (excluding ACAD) $76.05M+16.8%+34.8%58.5%

Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
Deferred Income Tax0000(249.88M)
Stock-Based Compensation63.62M68.2M66.42M67.05M0
Change in Working Capital(24.82M)37.99M18.13M4.16M(89.76M)
Accounts Receivables(16.12M)2.26M(39.27M)(2.35M)(43.54M)
Inventory(4.21M)2.42M(28.81M)(49.55M)(18.2M)
Accounts Payables(1.62M)5.87M4.8M(1.35M)(5.29M)
Other Working Capital(2.88M)27.44M81.41M57.4M(22.73M)
Other Non-Cash Items75K(6.28M)(12.12M)(155.82M)46.71M
Operating Cash Flow(125.66M)(114.04M)16.7M157.72M109.84M
Capital Expenditures(1.12M)0(40.05M)(523K)(4.69M)
Acquisitions (Net)69.98M0(32.05M)00
Purchases of Investments(492.8M)(363.17M)(369.99M)(505.1M)(692.57M)
Sales of Investments422.82M436.42M442.03M328.57M493.53M
Other Investing Activities(69.98M)032.05M146.52M0
Investing Cash Flow(71.1M)73.24M32M(30.54M)(302.56M)
Debt Repayment00000
Common Stock Issued18.16M8.2M25.13M6.85M49.88M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow18.16M8.2M25.13M6.85M49.88M
Effect of Forex Changes7K6K(18K)(94K)951K
Net Change in Cash(178.59M)(32.59M)73.81M133.93M(141.89M)
Free Cash Flow(126.78M)(114.04M)(23.35M)157.2M105.15M

ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.